Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral Febuxostat in Subjects With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemia (serum urate ≥8.0 mg/dL) and gout by Chinese Rheumatism Association Criteria;~* Renal function defined as a serum creatinine level of \< 2.0 mg/dL and creatinine clearance of \> 20 milliliters per minute (mL/min) by Cockcroft and Gault formula;~* No gout flare 2 weeks beforehand during 2-week screening period.~Exclusion Criteria:~* Pregnancy or lactation;~* Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (\>325 mg) or other salicylates;~* Body Mass Index (BMI) \>50 kilogram per meter²(kg/m²);~* A history of active liver disease, or hepatic dysfunction;~* A history of bronchial asthma;~* A history of renal calculi or thyroid disease;~* Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis and bone tumor;~* Intolerance to allopurinol and Ibuprofen;~* Alcohol intake of ≥ 14 drinks/week;~* Clinically significant medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 40 mg QD (Type: EXPERIMENTAL): Febuxostat 40 mg, orally, once daily for up to 24 weeks
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): Febuxostat 80 mg, orally, once daily for up to 24 weeks
- Allopurinol 100mg QD (Type: ACTIVE_COMPARATOR): Allopurinol 100mg, orally, three times daily for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).